跳至主要内容
临床试验/CTRI/2022/12/048144
CTRI/2022/12/048144已完成未知

An Open label clinical study to evaluate the safety and efficacy of molecular medicine and CelWel

Carmel Research Consultancy Private Limited0 个研究点目标入组 15 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Patients with long covid symptoms
  • 2.Male and female subjects ranging in age from 18
  • to 99 years.
  • 3.Willingness to follow the protocol requirements
  • as evidenced by written, Informed Consent.
  • 4.Mentally, physically and legally eligible to
  • give informed consent.
  • 5.Willingness to complete study questionnaires.

排除标准

  • 1.Patients with pre-existing other severe systemic
  • disease necessitating long-term medication.
  • 2.History of cancer, including solid tumours,
  • hematologic malignancies and carcinoma in situ
  • 3.Any vascular or systemic disorder which could
  • affect any of the efficacy assessments
  • 4.Subjects received other medication (anti-viral)
  • within the 36 hours before entry into the study
  • 5.Evidence of significant uncontrolled co-morbid
  • disease which would jeopardize patient
  • participation
  • 6.Patients hospitalized or requiring oxygen
  • 7.Patients unable to take oral medication

研究者

发起方
Carmel Research Consultancy Private Limited

相似试验